Emergent BioSolutions Inc. is a global specialty pharmaceutical company, which offers specialized products to governments and healthcare providers. The company derives most of its revenue from one product, BioThrax, which is the only FDA-licensed vaccine for the prevention of anthrax disease. In 2015, about 56% of the company’s revenue came from the sale of BioThrax with the remainder coming from the sale of their other biodefense products, biosciences products, and contract manufacturing.
{iframe}http://seekingalpha.com/article/3979224-emergent-biosolutions-underlying-value-realized-following-aptevo-spin?auth_param=gq4v:1bm5ujh:6136ebe22b7c951a050bfa3c7dbdf7a7&utoken=77cea408193abfd0b8876d8484dacaab{/iframe}